Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Rhinovirus Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Rhinovirus" report has been added to ResearchAndMarkets.com's offering.
The Rhinovirus Infection pipeline guide presents complete overview of drugs currently being developed for Rhinovirus Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include- Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma- Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
Report Description:
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rhinovirus Infection pipeline candidate. Research and Development progress along with latest news related to each of the Rhinovirus Infection pipeline candidates is included.
Major companies participating in therapeutic development of Rhinovirus Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Rhinovirus Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rhinovirus Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Rhinovirus Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Key Topics Covered:
I. Key Findings
1. Companies Investing in Rhinovirus Infection Pipeline include
Number of Companies with Rhinovirus Infection projects in pre-clinical Development
Number of Companies with Rhinovirus Infection projects in Clinical Development
2. Pipeline Candidates include
Rhinovirus Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Rhinovirus Infection Pipeline Agents in Clinical Development stage
Rhinovirus Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Rhinovirus Infection Pipeline agents
II. Insights into Rhinovirus Infection Pipeline -
1. Disease Overview
Introduction to Rhinovirus Infection
Symptoms and Causes of Rhinovirus Infection
Treatment or Prevention Options for Rhinovirus Infection
Other Details
2. Phase wise Pipeline Compounds
Rhinovirus Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Rhinovirus Infection Pipeline- Phase 1 stage Drugs
Rhinovirus Infection Pipeline- Phase 2 stage Drugs
Rhinovirus Infection Pipeline- Phase 3 stage Drugs
Rhinovirus Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Rhinovirus Infection Pipeline Compounds
4. Rhinovirus Infection Pipeline by Mechanism of Action
III. Rhinovirus Infection Pipeline Compound Details
- TVB-3567
- ARMS-I
- HRV 3C protease Inhibitor
- rhinovirus vaccine
- drug for Rhinovirus Infections
- polyvalent rhinovirus vaccine
- PrEP-001
- HRV Vaccine
- antiviral therapeutics
- VVX003
- Monoclonal Antibodies for Rhinovirus Infections
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. Rhinovirus Infection Pipeline Company Briefs
- 3-V Biosciences Inc
- ARMS Pharmaceutical LLC
- AstraZeneca Plc
- Biological Mimetics Inc
- Haplogen GmbH
- Meissa Vaccines Inc
- PrEP Biopharm Ltd
- Prokarium Ltd
- Secarna Pharmaceuticals GmbH&Co.KG
- Viravaxx AG
- Zebra Biologics Inc
V. Latest News and Developments in Global Rhinovirus Infection Pipeline Market
VI. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/738krr/rhinovirus?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.